OPKO Health (LTS:0KCS) Quality Rank


LTS:0KCS OPKO Health Inc LTS:0KCS
54 GF Score
Price $1.53
GF Value $1.06
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is OPKO Health Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

OPKO Health Quality Rank Related Terms

LTS:0KCS
54GF Score
OPKO Health Inc LTS:0KCS
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is OPKO Health (LTS:0KCS) Overvalued in 2026?

Based on GuruFocus' analysis, OPKO Health stock appears to be overvalued. The current stock price of $1.53 is trading 43.9% above its estimated GF Value™ of $1.06. GuruFocus considers OPKO Health to be Significantly Overvalued.

Key valuation signals for LTS:0KCS:

  • Quality Rank:
  • GF Value™: $1.06 vs. price of $1.53 (43.9% above fair value)
  • GF Score™: 54/100 with 7 warning signs

No single metric tells the full story. See the LTS:0KCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

OPKO Health Business Description

Address 4400 Biscayne Boulevard, Miami, FL, USA, 33137
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
54GF Score

Get the complete analysis for LTS:0KCS

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.53
Price
$1.06
GF Value